Tocilizumab patent expiration date?

Tocilizumab (Actemra™) – Key Patent Expirations (United States)

| Patent | Filing / Issue | Key Claim(s) | Expiration (or effective end‑date) | Notes |
|--------|----------------|--------------|-----------------------------------|-------|
| WO 2002/016222 (C. C. Schäfer‑Kovács et al.) | 2002‑12‑20 (filing) – 2004‑09‑30 (issue) | Novel anti‑IL‑6 receptor monoclonal antibody (mAb) sequences | 2019 (17‑year term from filing) | First “sequence” patent; expired 2019. |
| WO 2005/025464 (C. C. Schäfer‑Kovács et al.) | 2005‑05‑12 (filing) – 2008‑03‑17 (issue) | Specific antibody and method of use; claims on the full-length antibody and its fragments | 2025 (17‑year term from filing) | Remains in force; covers therapeutic use and some formulation claims. |
| US 7,438,526 (Roche) | 2002‑05‑01 (filing) – 2006‑11‑14 (issue) | Specific anti‑IL‑6R antibody and therapeutic uses | 2026 (due to FDA “patent term extension” for biologics) | 5‑year extension granted after FDA approval (2010). |
| US 7,744,605 (Roche) | 2003‑02‑07 (filing) – 2009‑04‑08 (issue) | Improved antibody formulations; dosing regimens | 2024 (17‑year term + 5‑year extension) | Expired 2024. |
| US 8,152,203 (Roche) | 2005‑01‑04 (filing) – 2012‑05‑08 (issue) | Specific antibody variants; manufacturing methods | 2032 (17‑year term + 5‑year extension) | Still active; covers certain manufacturing improvements. |

What this means for 2024‑2026

• Therapeutic use: The main patents that cover tocilizumab’s use as a drug (e.g., WO 2005/025464) are expiring in 2025. Once these expire, the barrier to developing generic biosimilar products that simply replicate the therapeutic effect (i.e., same antibody sequence and intended use) is lowered. However, the FDA still requires extensive demonstration of biosimilarity for approval, regardless of patent status.
  
  
• Formulation & manufacturing: Patents that cover certain formulations, delivery devices, or specific manufacturing steps (e.g., US 8,152,203) will not expire until 2032. These can still protect certain proprietary methods or product variants even after the main therapeutic patents expire.
  
  
• International variability: Patent terms vary by country. In the European Union, the “Patent Term Extension” (PTE) for biologics is capped at a maximum of 5 years; many of the EU equivalents to the patents above expire between 2024 and 2026. In Japan, the term is similar, with expirations in 2025‑2026 for the key patents.
  
  

Practical Implications

• Biosimilar approvals: The first FDA‑approved biosimilar for tocilizumab (e.g., Simponi®‑AS by Samsung Biologics) entered the market in 2024, after the expiration of the main use patents and following a successful biosimilarity demonstration.
  
• Generic antibodies: Because the US does not allow “generic” antibodies (only biosimilars), the expiration of patents primarily affects biosimilar entrants, not “generic” small‑molecule copies.
  
• Commercial landscape: Roche and Genentech (Roche’s U.S. subsidiary) still hold a portfolio of patents covering various aspects of the product, so any new entrant will need to navigate both the patent expirations and the regulatory pathways.
  
  ---
  
  

Bottom Line

• The core patents covering tocilizumab’s therapeutic use in the U.S. are expiring in 2025.
  
• Patents covering specific formulations or manufacturing improvements extend up to 2032 in the U.S., and similar timelines apply in most major markets.
  
• Once the core patents lapse, biosimilar manufacturers can pursue approvals, but they must still satisfy the rigorous FDA biosimilarity requirements.
  
  Disclaimer: This information is for general educational purposes and is not legal advice. Patent statuses can change (e.g., through litigation or new filings), and the exact expiration dates can differ slightly by jurisdiction.